11 janvier 2021
Theratechnologies Announces US$40 Million Bought-Deal Public Offering Of Units
Montreal, QC – January 11, 2021 – Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it has entered into an agreement with a syndicate of Canadian underwriters (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a bought-deal basis, 14,546,000 units of the Company (the “Units”) for aggregate gross proceeds to the Company of US$40,001,500 (equivalent to approximately C$51,081,915) (the « Offering« ) at a price of US$2.75 per Unit (equivalent to approximately C$3.51 per Unit).
Each Unit shall be comprised of one common share of the Company (each a « Common Share« ) and one-half of one Common Share purchase warrant of the Company (each whole warrant, a « Warrant« ). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of US$3.18 (equivalent to approximately C$4.06) at any time up to 36 months from the closing of the Offering.